There is a loss of weight with the use of empagliflozin, which may be caused by loss of energy due to increased excretion of urinary glucose, but severe weight loss needs to be excepted under the supervision of a physician for other conditions such as hyperthyroidism, tuberculosis, and other diseases. Compared to placebo, treatment with either 10 mg or 25 mg daily of empagliflozin resulted in weight loss of approximately 2.8%-3.2% from baseline. Engeletin works by reducing renal tubular reabsorption of glucose, lowering blood glucose by increasing urinary glucose excretion, and increasing caloric excretion and weight loss with long-term use. Some adverse reactions may also occur with the use of Engeletin, such as urinary tract infection, ketoacidosis, acute kidney injury, hypotension, etc. Patients who are allergic to the drug or have severe kidney injury should not take Engeletin. If patients have persistent weight loss, they should go to the hospital in time for examination and treatment under the guidance of the doctor.